Cargando…

HER3 expression and MEK activation in non-small-cell lung carcinoma

AIM: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. MATERIALS & METHODS: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manickavasagar, Thubeena, Yuan, Wei, Carreira, Suzanne, Gurel, Bora, Miranda, Susana, Ferreira, Ana, Crespo, Mateus, Riisnaes, Ruth, Baker, Chloe, O’Brien, Mary, Bhosle, Jaishree, Popat, Sanjay, Banerji, Udai, Lopez, Juanita, de Bono, Johann, Minchom, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162178/ https://www.ncbi.nlm.nih.gov/pubmed/34084213 http://dx.doi.org/10.2217/lmt-2020-0031

Ejemplares similares

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2020)

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2021)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020)

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
por: Minchom, Anna, et al.
Publicado: (2019)

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, Wanyuan, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
por: Pal, Abhijit, et al.
Publicado: (2021)

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
por: Banerjee, Susana, et al.
Publicado: (2022)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, W., et al.
Publicado: (2020)

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy
por: Tiu, Crescens, et al.
Publicado: (2021)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015)

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature
por: Lote, Hazel, et al.
Publicado: (2014)

Weakly supervised segmentation models as explainable radiological classifiers for lung tumour detection on CT images
por: O’Shea, Robert, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
por: Hindocha, Sumeet, et al.
Publicado: (2021)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
por: Joshi, K., et al.
Publicado: (2020)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
por: O’Carrigan, Brent, et al.
Publicado: (2018)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
por: Zafeiriou, Zafeiris, et al.
Publicado: (2019)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy
por: Castagnoli, Francesca, et al.
Publicado: (2022)

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice
por: Abdelraouf, Fatma, et al.
Publicado: (2015)

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach
por: Pender, Alexandra, et al.
Publicado: (2015)

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
por: Minchom, Anna, et al.
Publicado: (2018)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
por: Perkins, Geraldine, et al.
Publicado: (2012)

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers
por: Bon, Giulia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vfm1a7mgc6pkjetp6eptui6e3o